Scripps Research Unveils 1-Week Nanodisc Platform to Map Antibody Attacks on HIV and Ebola
Updated
Updated · SciTechDaily · Jun 15
Scripps Research Unveils 1-Week Nanodisc Platform to Map Antibody Attacks on HIV and Ebola
3 articles · Updated · SciTechDaily · Jun 15
Summary
Nature Communications published a Scripps Research platform that embeds viral surface proteins in lipid nanodiscs, letting scientists study antibody binding in a membrane-like setting closer to real viruses.
The system addresses a key gap in vaccine research: standard lab-made proteins often omit membrane-anchoring sections, obscuring how antibodies recognize and disable targets near the protein base.
HIV tests produced structural images of a conserved membrane-proximal region, revealing interactions unseen in isolated proteins and suggesting how broadly neutralizing antibodies disrupt viral machinery.
Ebola experiments showed the method also works beyond HIV, and the team said similar membrane-bound proteins from influenza and SARS-CoV-2 could be studied the same way.
Processes that previously took a month or more can now be done in about a week, potentially speeding comparison of vaccine candidates and next-generation vaccine design.
The nanodisc platform, developed by Scripps Research, IAVI, and partners, marks a major advance in vaccine design by solving a long-standing challenge: studying complex viral surface proteins like those of HIV and Ebola. Previously, scientists could only work with incomplete versions of these proteins, making it difficult to understand how protective antibodies interact with viruses in their natural state. The nanodisc platform overcomes this by allowing researchers to examine full viral proteins in an environment that closely mimics their natural setting, leading to deeper insights and paving the way for more effective vaccines against challenging pathogens.